Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time . The presentation will be webcast live and
View HTML
Toggle Summary Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Data Continue to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma Results from Patients Treated in North America Demonstrate Two-Year Modified Progression-Free Survival of 84.3 Percent in the ADCETRIS
View HTML
Toggle Summary Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jun. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc.
View HTML
Toggle Summary Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey , M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc.
View HTML
Toggle Summary Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting in Chicago, Illinois ,
View HTML
Toggle Summary Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
BOTHELL, Wash. --(BUSINESS WIRE)--May 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Reports First Quarter 2018 Financial Results
-Record ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $95.4 Million in the First Quarter- -ADCETRIS Approved by FDA in Frontline Stage III/IV Classical Hodgkin Lymphoma- -ECHELON-2 Data Expected in 2018- -Conference Call Today at 4:30 p.m. ET - BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 12, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Apr. 5, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a
View HTML
Toggle Summary Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Mar. 26, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , “Astellas”) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy Designation to
View HTML